Maxim Group Maintains Their Buy Rating on Actinium Pharmaceuticals (ATNM)


Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM) today and set a price target of $3. The company’s shares opened today at $0.56.

McCarthy noted:

“Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20.”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.7% and a 37.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Moderate Buy with an average price target of $4.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.32 million. In comparison, last year the company had a GAAP net loss of $5.16 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts